[HTML] Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial …
LM McCormick, SP Hoole, PA White, PA Read… - JACC: Cardiovascular …, 2015 - Elsevier
Abstract Objectives This study sought to determine whether pre-treatment with intravenous
glucagon-like peptide-1 (GLP-1)(7-36) amide could alter myocardial glucose use and
protect the heart against ischemic left ventricular (LV) dysfunction during percutaneous
glucagon-like peptide-1 (GLP-1)(7-36) amide could alter myocardial glucose use and
protect the heart against ischemic left ventricular (LV) dysfunction during percutaneous
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论